Status:
UNKNOWN
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
Lead Sponsor:
Jiangsu Cancer Institute & Hospital
Conditions:
Advanced Colorectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.
Detailed Description
XELOX is a commonly used chemotherapy regimen, and XELIRI has also been widely used in the second-line treatment. XELOX and XELIRI adopt the three-week regimen, and the single dose of oxaliplatin and ...
Eligibility Criteria
Inclusion
- 18-75 years old;
- Patients with advanced colorectal adenocarcinoma diagnosed by histopathology, or with metastasis more than 12 months after radical operation, and the metastasis could not be removed;
- ECOG score ≤ 2, estimated survival time ≥ 3 months;
- Leucocytes ≥ 3.5 × 109 / L, neutrophils ≥ 1.5 × 109 / L, hemoglobin ≥ 100g / L, platelets ≥ 80 × 109 / L, serum liver enzyme in patients without liver metastasis is not higher than 2.5 times of the upper limit of normal value, serum liver enzyme in patients with liver metastasis is not higher than 5 times of the upper limit of normal value, serum bilirubin level is not higher than 1.5 times of the upper limit of normal value, serum creatinine level is not higher than 1.5 times of the upper limit of normal value;
- At least one lesion can be measured by CT or MRI;
- No other history of malignant tumor;
- Those who are fertile but willing to take contraceptive measures;
- Sign the written informed consent.
Exclusion
- Patients with allergic, hypersensitive constitution and autoimmune diseases;
- There are only unmeasurable lesions, such as hydrothorax and ascites, carcinomatous lymphangitis, diffuse liver invasion and bone metastasis; No measurable or non assessable lesions;
- Pregnant or lactated women;
- Uncontrolled symptomatic brain metastasis or mental disorder can not correctly describe subjective symptoms;
- Major organ failure;
- Affecting drug administration, absorption, distribution, metabolism, excretion, etc. the patient has uncontrollable epileptic attack, central nervous system disorder or loss of self-knowledge due to mental disease, physiological or pathological malnutrition, chronic diarrhea, and cachexia;
- Patients with complete or incomplete ileus；
- Patients with serious heart disease or history, including documented history of congestive heart failure, high-risk uncontrolled heart rate disorder, angina requiring drug treatment, clinically clear history of heart valve disease, serious myocardial infarction and stubborn hypertension;
- Severe uncontrollable infection;
- Alcohol and /or drug abuse or poor compliance of the investigator's judgment.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04324476
Start Date
September 1 2019
End Date
June 1 2023
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Cancer Institute & Hospital
Nanjing, Jiangsu, China, 210009